Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration

Abstract

The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a validated instrument specifically designed to ascertain damage in SLE; this instrument has been applied mainly to Caucasians and African-American SLE patients. The objective of this study was to assess damage using the SLICC/ACR Damage Index in Mexican SLE patients. The SLICC/ACR Damage Index was applied to 210 consecutive SLE patients with disease of variable duration. The SLICC/ACR Damage Index was assessed by review of hospital clinical records, interview and physical examination. One hundred and seventeen (55.5%) patients had some damage. The proportion of patients with damage increased significantly with disease duration (33% at 1–60 months, 66% at 61–120 months and 70% at ≥121 months, P < 0.001). The main organ systems involved were musculoskeletal (osteonecrosis), neuropsychiatric (neuropathy, seizures), gonadal (amenorrhea prior to age 40 years), ocular (cataracts), renal (glomerular filtration < 50%) and peripheral vascular (permanent damage by venous thrombosis). Damage was frequent, increased over time, particularly for ocular, renal, musculoskeletal and gonadal. Patients who experienced damage were older, had a longer disease duration, a greater number of ACR criteria at diagnosis, and were more likely to have renal involvement and antibodies to dsDNA. The damage occurred in many different domains and started to develop early after disease onset. Mexican patients had more peripheral vascular and gonadal involvement compared with published data from non-Hispanic SLE populations.

Keywords

SLE damage disease course prognosis outcome

Get full access to this article

View all access options for this article.

References

Fessel WJ . Systemic lupus erythematosus in the community: incidence, prevalence outcome and first symptoms; the high prevalence in black women . Arch Intern Med 1974; 134: 1027–1035 .

Hochberg MC . The incidence of systemic lupus erythematosus in Baltimore, Maryland, 1970–1977 . Arthritis Rheum 1985; 28: 80–86 .

Ward MM , Studenski S . Clinical manifestations of systemic lupus erythematosus: identification of racial and socioeconomic influences . Arch Intern Med 1990; 150: 849–853 .

Ballou SP , Khan MA , Kushner I . Clinical features of systemic lupus erythematosus: differences related to race and age of onset . Arthritis Rheum 1982; 25: 55–60 .

Reveille JD , Bartolucci A , Alarcón GS . Prognosis in systemic lupus erythematosus: negative impact of increasing age at onset, black race and thrombocytopenia, as well as causes of death . Arthritis Rheum 1990; 33: 37–48 .

Studenski S et al. Survival in systemic lupus erythematosus: an analysis of demographic features . Arthritis Rheum 1987; 30: 1326–1332 .

Kaslow RA , Masi AT . Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States . Arthritis Rheum 1978; 21: 473–479 .

Ginzler EM et al. A multicenter study of outcome in systemic lupus erythematosus. Entry variables as predictors of prognosis . Arthritis Rheum 1982; 25: 601–611 .

Kaslow RA . High rate of death caused by systemic lupus erythematosus among U.S. residents of Asian descent . Arthritis Rheum 1982; 25: 414–418 .

10.

Ward MM , Pyun E , Studenski S . Long-term survival in systemic lupus erythematosus: patient characteristics associated with poorer outcomes . Arthritis Rheum 1995; 38: 274–283 .

11.

Gladman DD . Prognosis of systemic lupus erythematosus and the factors that affect it . Curr Opin Rheumatol 1991; 3: 789–796 .

12.

Gladman D et al. Systemic Lupus International Collaborating Clinics: conference on assessment of lupus flare and quality of life measures in SLE . J Rheumatol 1996; 23: 1953–1955 .

13.

Gladman DD et al. Systemic lupus international collaborative clinics: development of a damage index in systemic lupus erythematosus . J Rheumatol 1992; 19: 1820–1821 .

14.

Gladman D et al. The development and initial validation of the systemic lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus . Arthritis Rheum 1996; 39: 363–378 .

15.

Gorgos L , Goldman D , Petri M . The ACR/SLICC damage index in systemic lupus erythematosus . Arthritis Rheum 1993; 36 (Suppl.): S68-S68 .

16.

Karlson EW et al. Predictors of disease activity and organ damage in SLE . Arthritis Rheum 1994; 37 (Suppl.): S199-S199 .

17.

Straaton KV et al. Determinants of disease damage in Hispanic (H), African-American (AA) and Caucasian (C) SLE patients . Arthritis Rheum 1996; 39 (Suppl.): S111-S111 .

18.

Stoll T , Seifert B , Isenberg DA . SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus . Br J Rheumatol 1996; 35: 248–254 .

19.

Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271–1277 .

20.

Rubin LA , Urowitz MB , Gladman DD . Mortality in systemic lupus erythematosus: the biomodal pattern revised . Q J Med 1985; 55: 87–98 .

21.

Boumpas DT et al. Risk of sustained amenorrhoea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Intern Med 1993; 119: 366–369 .

22.

Martin K , Kavanaugh A , Middleton G , Lipsky P . The prevalence of nephritis in Hispanic patients with systemic lupus erythematosus . Arthritis Rheum 1994; 37 (Suppl.): S179-S179 .

23.

Dubois EL , Cozen L . Avascular (aseptic) bone necrosis associated with lupus erythematosus . J Am Med Assoc 1960; 174: 966–984 .

24.

Petri M . Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update . Arthritis Care Res 1995; 8: 137–145 .

25.

Migiliaresi S et al. Avascular osteonecrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies . Lupus 1994; 3: 37–41 .

26.

Rascu A et al. Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation . Lupus 1996; 5: 323–327 .

27.

Austin HA et al. Prognostic factor in lupus nephritis: contribution of renal histologic data . Am J Med 1983; 75: 382–391 .

28.

Esdaile JM et al. The time-dependence of long-term predictors in lupus nephritis . Arthritis Rheum 1994; 37: 359–368 .

29.

Ginzler EM , Felson DT , Anthony JM , Anderson JJ . Hypertension increases the risk of renal deterioration in systemic lupus erythematosus . J Rheumatol 1993; 20: 1694–1700 .

30.

Nossent HC et al. Contribution of renal biopsy data in predicting outcome in lupus nephritis . Arthritis Rheum 1990; 33: 970–977 .

31.

Ciruelo E , De la Cruz J , Loópez I , Goómez-Reino JJ . Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide . Arthritis Rheum 1996; 39: 2028–2034 .

32.

Kovacs JAJ , Urowitz MB , Gladman DD . Dilemmas in neuropsychiatric lupus . Rheum Dis Clin North Am 1993; 19: 795–813 .